US-based pharmaceutical company Moderna confirmed that it has been working on the development of hantavirus vaccines in collaboration with the Vaccine Innovation Center of Korea University College of Medicine (VIC-K). This comes after an outbreak of hantavirus occurred on a Dutch cruise ship that sailed from Argentina and disembarked its passengers and crew in the Canary Islands on May 10. At least three people aboard the MV Hondius died, and several cases were reported as serious. Moderna is the Cambridge, Massachusetts-based biotechnology company that perfected messenger RNA (mRNA) vaccines during the Covid-19 pandemic. Following the announcement that Moderna was developing a hantavirus vaccine using this same technology, the drugmaker's stock rose from $49 on May 7 to $55 the next day. But it is important to note that Moderna did not begin work on immunization in the wake of the outbreak at MV Hondius . In fact, the drugmaker undertook this collaborative project with VIC-K in 2023.…